Marta López‐Yurda

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Myriam Chalabi, Lorenzo F. Fanchi, Krijn K. Dijkstra et al. · Nature Medicine · 2020 · 1.4K citations · Full text

Medicine, Oncology, Pathology +14

First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group

Marinde J. G. Bond, Karen Bolhuis, O. J. L. Loosveld et al. · The Lancet Oncology · 2023 · 168 citations · Full text

Medicine, Oncology, Gastrointestinal Oncology +16

Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial

S. Lot Aronson, Marta López‐Yurda, Simone N. Koole et al. · The Lancet Oncology · 2023 · 121 citations · Full text

Medicine, Oncology, Surgery +16

Relapse of Wilms' tumour and detection methods: a retrospective analysis of the 2001 Renal Tumour Study Group–International Society of Paediatric Oncology Wilms' tumour protocol database

Jesper Brok, Marta López‐Yurda, Harm van Tinteren et al. · The Lancet Oncology · 2018 · 107 citations · Full text

Medicine, Oncology, Pathology +14

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

Marie José Kersten, Julia Driessen, Josée M. Zijlstra et al. · Haematologica · 2020 · 102 citations · Full text

Medicine, Oncology, Pharmacotherapy +15